Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Germline variants that did not affect gene function nevertheless affected multiple aspects of breast cancer risk, via their visibility to the immune system and its reactions. Perhaps most surprisingly, the same genetic constellations that were protective at the very earliest stage of breast cancer, stage 0 or ductal carcinoma in situ, were associated with worse outcomes once a tumor had become invasive.
Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.
Odimma Therapeutics SAS has developed ODI-2001, a new biological from the combination of neoantigen-expressing DNA vector, an anti-CTLA-4 antibody and an attenuated poxvirus with the aim of increasing the immune response against tumors.
Trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugates became a topic of talk during the recent American Society of Clinical Oncology meeting in Chicago.
Astrazeneca plc’s blockbuster Enhertu continued to garner attention as new data released at the American Society of Clinical Oncology (ASCO) annual meeting show the antibody-drug conjugate demonstrated strong progression-free survival in metastatic breast cancer patients. Puma Biotechnology Inc. had advances of its own at ASCO with new biomarker findings from a phase II study of alisertib, an aurora protein kinase 2 inhibitor, in endocrine-resistant metastatic breast cancer.
Xuanzhu Pharma Co. Ltd. has divulged poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, epilepsy, hyperlipidemia, ischemia, osteoarthritis, pain and Alzheimer’s disease.
Petra Pharma Corp. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly H1047R and/or E545K mutant allosteric inhibitors. They are described as potentially useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
